Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
about
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individualsAngiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney diseaseEffect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analysesAssessing the Validity of Surrogate Outcomes for ESRD: A Meta-AnalysisEffect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trialsAntihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis.Decreased insulin secretion and increased risk of type 2 diabetes associated with allelic variations of the WFS1 gene: the Data from Epidemiological Study on the Insulin Resistance Syndrome (DESIR) prospective study.Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.Diabetic nephropathy: preventing progressionComparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Safety of ACE inhibitor therapies in patients with chronic kidney disease.Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy.Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetesA Case for Early Screening for Diabetic Kidney Disease.Antihypertensive medications for risk reduction of first and recurrent ischemic stroke.NMR-based prediction of cardiovascular risk in diabetes.Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.Ramipril in the treatment of vascular diseases.Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.Mortality rates in trials of subjects with type 2 diabetes.Blood pressure control and prevention of stroke.Antihypertensive agents in patients with diabetes: trade-off between renal and cardiovascular protection.The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications.Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), DiaPerindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials.Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.A guide to the management of blood pressure in the diabetic hypertensive patient.The ADVANCE cardiovascular risk model and current strategies for cardiovascular disease risk evaluation in people with diabetesThe role of RAS modification for primary and secondary stroke prevention.Effectiveness of blood pressure lowering: evidence-based comparisons between men and women.Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.Metabolomics and ischaemic heart disease.Prehypertension--prevalence, health risks, and management strategies.Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
P2860
Q24186039-D74D9EA1-D039-4C86-B753-10C4F27B02F7Q24244197-6DAC57C0-5027-4420-A810-3085A1AEAFCDQ26766025-C47F2980-40FA-4AA4-9973-D3E79DA3E14AQ26863404-F05F1562-3A82-4CA4-ACD3-9234BFE37BFDQ28087109-734B77FD-E966-42A5-84FC-EC4A9FE99FE2Q30619473-457C13E0-C59E-4F45-8951-B57617CA606CQ33762350-24432649-FE83-4167-BDF1-E7D5353D658CQ33836604-EAFBA39D-9791-4235-96E6-EC31991CA63DQ33850444-BD118AE9-B82A-4E07-A31B-C6C483F00084Q34380070-D14D456D-57F5-4F87-957D-FBDABAFEA7F3Q34434606-FC37386B-F24C-4AC4-99FB-21BFF1366717Q34979484-53D2EE93-CC4E-430A-8DDB-76DC144ACAF3Q35025425-F6034D00-2F1D-40BA-ADEE-A7A16944B631Q35050798-799C342E-5E69-4CC4-99AF-768AD4C79B04Q35073993-72E6B0E1-38D5-4358-A1EB-3A0295053896Q35567422-FFE1BAE4-CD6F-4047-986E-908C2E8D4DADQ35925696-84B6DA57-099D-4CFD-9008-D4A5FE1C4293Q36145624-22C983DA-2F59-4A87-AFEF-718A2B4A5631Q36210252-CC4260C9-CA28-44DE-A618-77B604254BCCQ36249938-15188D27-559A-4516-B9CA-410B8395E235Q36289427-9F76E9E7-0DD3-4A6C-A91E-613C7516B4BEQ36366129-D1364E83-26B5-42DF-B2E5-77B5E25A9EC6Q36390821-1D80A2FE-2DB1-41DD-B484-33D3D5F076F9Q36549280-35FD10F0-42C4-4593-8874-00B527E9DEB9Q36836587-597599FE-CC2B-4689-90E7-DF73377DAB36Q36842087-A71BF146-6DAB-452F-95A8-E926D01D6B24Q37041380-C5D410D0-4027-4AE3-8290-63A2CB2D3D54Q37104532-BC09D898-FAEB-4317-A89C-A227EC8AC5ACQ37213061-44F92FBD-FF0A-44A7-8A04-EE1FA1472854Q37278044-5ABB2382-A33F-4E98-92A0-8D3B3F6EE182Q37292868-1B1D86DD-BCF2-454B-9347-D2DD6BBDB034Q37492556-3D74EC69-1B2B-43D8-BDA8-0BCAB24B5074Q37516832-B29BB18F-40AC-4D2F-9C2F-B315461ABE32Q37566079-1A10061A-991E-4573-87FA-E54C880EA615Q37688159-874C714C-1CCB-49E3-B383-54D6C4696439Q37882756-E83745EB-B19E-42B9-9B8C-E1F879D45683Q37970579-80AA16F4-8A59-4214-BFC5-5F97FAC2E22CQ38060209-0BC7E48E-9215-489F-97D9-15244CF2A95FQ38357890-7B349304-9030-4445-A270-F6D53B866D31Q38714008-85E0F7DB-99BE-44D4-A0D0-46FE68B95F7E
P2860
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@ast
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@en
type
label
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@ast
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@en
prefLabel
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@ast
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@en
P2093
P2860
P921
P1433
P1476
Effects of low dose ramipril o ...... d trial (the DIABHYCAR study).
@en
P2093
DIABHYCAR Study Investigators
Gilles Chatellier
Johannes F E Mann
Joël Ménard
Michel Lievre
Michel Marre
Philippe Passa
P2860
P356
10.1136/BMJ.37970.629537.0D
P407
P577
2004-02-11T00:00:00Z